Get the Stockscreener App
1.55
5.44%
0.08
Pre-market:
1.89
0.34
+21.94%
Context Therapeutics Inc stock is traded at $1.55, with a volume of 1.01M.
It is up +5.44% in the last 24 hours and up +46.23% over the past month.
Context Therapeutics Inc is a clinical-stage biopharmaceutical company advancing medicines for solid tumors. The development team is advancing a pipeline of various therapies with a primary focus on treating female, hormone-dependent cancer, including breast, ovarian, and endometrial cancer. The company's preclinical program, CTIM-76, is an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody (bsAb) that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6.
See More
Previous Close:
$1.47
Open:
$1.43
24h Volume:
1.01M
Relative Volume:
1.96
Market Cap:
$142.41M
Revenue:
-
Net Income/Loss:
$-30.15M
P/E Ratio:
-1.7033
EPS:
-0.91
Net Cash Flow:
$-31.63M
1W Performance:
+37.17%
1M Performance:
+46.23%
6M Performance:
+145.33%
1Y Performance:
+30.25%
1-Day Range:
$1.40
$1.61
1-Week Range:
$1.09
$1.61
52-Week Range:
$0.49
$1.61
Context Therapeutics Inc Stock (CNTX) Company Profile
Name
Context Therapeutics Inc
Sector
Industry
Phone
267-225-7416
Address
2001 MARKET STREET, PHILADELPHIA
Compare CNTX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CNTX
Context Therapeutics Inc
|
1.55 | 135.06M | 0 | -30.15M | -31.63M | -0.91 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.13 | 115.03B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
776.31 | 81.12B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
400.17 | 52.54B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
839.99 | 51.78B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
177.12 | 37.12B | 447.02M | -1.18B | -906.14M | -6.1812 |
Context Therapeutics Inc Stock (CNTX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-18-25 | Initiated | Guggenheim | Buy |
| Apr-21-25 | Initiated | William Blair | Outperform |
| Jan-08-25 | Initiated | JMP Securities | Mkt Outperform |
| Nov-25-24 | Initiated | D. Boral Capital | Buy |
| May-16-24 | Initiated | Piper Sandler | Overweight |
Context Therapeutics Inc Stock (CNTX) Latest News
Why GH Research Shares Are Trading Higher By 18%; Here Are 20 Stocks Moving Premarket - Benzinga
Raconteur Global Resources Limited Inches Toward Key Resistance — Will It BreakChart Pattern Recognition & Small Budget Wealth Building - bollywoodhelpline.com
BDH Industries Limited Building a Base Near SupportHead and Shoulders Patterns & High Profit Trading Alerts - bollywoodhelpline.com
MACD Signals Flash Warning for Sagar Diamonds Limited StockEarnings Beat Highlights & Free Stock Price Trend Analysis - bollywoodhelpline.com
Why Context Therapeutics Inc. stock remains on buy listsCup and Handle Formations & High Profit Market Ideas - bollywoodhelpline.com
Jones Trading Initiates Coverage of Context Therapeutics (CNTX) with Buy Recommendation - Nasdaq
Context Therapeutics (NASDAQ:CNTX) Coverage Initiated by Analysts at Jones Trading - MarketBeat
This Blacksky Technology Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday - Benzinga
Aug Reactions: Why Context Therapeutics Inc. stock could benefit from AI revolutionPortfolio Gains Report & AI Powered Market Entry Strategies - moha.gov.vn
Published on: 2025-12-21 00:47:49 - Улправда
Will Context Therapeutics Inc. stock benefit from automation2025 Fundamental Recap & Growth Focused Stock Reports - Улправда
Is Context Therapeutics Inc. stock a buy before product launchesJuly 2025 Technicals & Free Weekly Watchlist of Top Performers - Улправда
Bearish Setup: Will Calidi Biotherapeutics Inc. stock benefit from upcoming earnings reportsJuly 2025 Levels & Weekly Stock Breakout Alerts - Улправда
Breakouts Watch: How Context Therapeutics Inc. stock compares to market leaders2025 Momentum Check & Community Verified Watchlist Alerts - Улправда
Context Therapeutics Earnings Notes - Trefis
Why Context Therapeutics Inc. stock could benefit from AI revolutionPortfolio Gains Summary & Risk Adjusted Buy/Sell Alerts - DonanımHaber
Why Context Therapeutics Inc. stock is a must watch in 2025Trade Signal Summary & Weekly Stock Performance Updates - DonanımHaber
Can Context Therapeutics Inc. stock hit record highs againTrade Signal Summary & Verified Momentum Stock Alerts - DonanımHaber
Context Therapeutics Inc. (NASDAQ:CNTX) Given Consensus Recommendation of “Moderate Buy” by Brokerages - Defense World
How Context Therapeutics Inc. stock compares to market leadersWeekly Gains Summary & Weekly Breakout Watchlists - Улправда
Can Forum Energy Technologies Inc. stock attract ESG capital inflowsWeekly Investment Summary & Technical Pattern Alert System - Улправда
Is ABR.PRD stock trading near support levelsWeekly Stock Analysis & Consistent Growth Stock Picks - Улправда
Context Therapeutics Inc. (NASDAQ:CNTX) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
SJVN Limited (533206) Stock Experiences Sudden DipMoving Average Strategies & Free Tremendous Portfolio Expansion - Bollywood Helpline
Cancer Drug Developers Secure Regulatory Clarity as FDA Reshapes Approval Standards - GlobeNewswire
Context Therapeutics (NASDAQ:CNTX) Shares Up 8.7%What's Next? - MarketBeat
Context Therapeutics (NASDAQ:CNTX) Shares Up 8.7% – What’s Next? - Defense World
Oncotelic Therapeutics Study Reveals Context-Dependent Biomarker Significance in Liver and Pancreatic Cancers - citybuzz -
Oncotelic Therapeutics and Brush and Key Foundation Announce Publication in International Journal of Molecular Sciences Highlighting Context-Dependent Biomarkers in Liver and Pancreatic Cancer - The Manila Times
Unpacking Q3 Earnings: CoStar (NASDAQ:CSGP) In The Context Of Other Data & Business Process Services Stocks - Yahoo Finance
Context Therapeutics Inc (CNTX) Clearly Signals Buy-Into the Stock: Don’t ignore the signals - setenews.com
Context Therapeutics Names Dr. Karen Smith as Interim Chief Medical Officer - MSN
Is Context Therapeutics Inc. stock attractive for growth ETFs2025 Volume Leaders & AI Powered Trade Plan Recommendations - Newser
Unpacking Q3 Earnings: Axon (NASDAQ:AXON) In The Context Of Other Aerospace and Defense Stocks - Yahoo Finance
CT-202, a tumor-selective pH-dependent Nectin-4/CD3 TCE - BioWorld MedTech
Context Therapeutics Inc. (NASDAQ:CNTX) Receives $5.40 Average Target Price from Brokerages - Defense World
Ag Growth International (AGGZF) Projected to Post Quarterly Earnings on Friday - Defense World
Context Therapeutics Inc. (NASDAQ:CNTX) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Context Therapeutics (NASDAQ:CNTX) Upgraded to “Sell” at Wall Street Zen - Defense World
Context Therapeutics (NASDAQ:CNTX) Upgraded to "Sell" at Wall Street Zen - MarketBeat
What drives Context Therapeutics Inc stock priceTrading Volume Trends & Affordable Growth Strategies - earlytimes.in
Jim Cramer Discusses Rockwell (ROK) Automation in the Context of Ongoing Industrial Revolution - Yahoo Finance
What technical charts say about Context Therapeutics Inc. stockWeekly Stock Analysis & Free Fast Gain Swing Trade Alerts - newser.com
Why analysts remain bullish on Context Therapeutics Inc. stockSwing Trade & Accurate Intraday Trading Signals - newser.com
Is Context Therapeutics Inc. stock a safe buy before earnings2025 Performance Recap & Technical Entry and Exit Alerts - newser.com
Is Context Therapeutics Inc. stock poised for growthJuly 2025 Decliners & Long-Term Growth Plans - newser.com
Unpacking Q3 Earnings: Amneal (NASDAQ:AMRX) In The Context Of Other Generic Pharmaceuticals Stocks - Yahoo Finance
Palvella Races Toward Key 2026 Readouts as Rare-Disease Pipeline Expands Rapidly - MyChesCo
Using portfolio simulators with Context Therapeutics Inc. includedMarket Growth Report & Long-Term Capital Growth Ideas - newser.com
Context Therapeutics Inc Stock (CNTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Context Therapeutics Inc Stock (CNTX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Levit Alex C. | Chief Legal Officer, Corp. Sec |
Jun 06 '25 |
Buy |
0.58 |
20,000 |
11,520 |
29,000 |
| Minai-Azary Jennifer Lynn | Chief Financial Officer |
Jun 06 '25 |
Buy |
0.64 |
40,010 |
25,486 |
80,010 |
0.57%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):